Jinwoo Bio

What Jinwoo Bio does

Jinwoo Bio Co., Ltd. (진우바이오) is a South Korea-based biotechnology company founded in May 2013 and headquartered in Yongin-si, Gyeonggi Province. The company specializes in commercializing the Solid Hyaluronic Acid Technology Platform (SHTP) — described as the world's first technology to solidify hyaluronic acid (HA) into various physical forms including film, thread, wool, and fabric sheet, in contrast to conventional liquid or gel HA products. The company holds 28 patents (15 domestic, 13 international) across Korea, US, Europe, Japan, and China, with 11 additional patents pending.

Jinwoo Bio's commercial product portfolio centers on medical devices and cosmetic applications of SHTP. The first commercial product, JiNu Patch — a Class II adhesive transparent wound dressing — was launched in March 2022. Planned product lines include HA Thread (solid HA facial filler for plastic surgery and dermatology), HA Wool (Class II wound dressing and Class III adhesion barrier), HA Fabric Sheet (multi-purpose burn/pressure ulcer dressing and mucosal DDS substrate), and the Hi-Aqua brand platform spanning HA-based cosmetic ingredients to finished products. The company's go-to-market is sales-led B2B, targeting Korean hospitals, dermatology clinics, and plastic surgery centers through a 1:1 website inquiry system, with stated intent to expand into Asia, US, and European markets.

The business model relies on direct medical device sales and cosmetic product distribution. Jinwoo Bio has raised approximately 3 billion KRW (~$2.2M USD) in a Series A bridge round in May 2023 led by Winvest Venture Investment and Oracle, with an additional funding round in May 2024. The company holds key regulatory credentials including NET (New Excellent Technology) certification from the Ministry of Health and Welfare (extended to August 2025), GMP certification, medical device manufacturing license, and HIRA registration enabling Korean national health insurance reimbursement. The company employs 11-50 staff and is led by CEO Kwon Dong-gun, who brings 25-26 years of hyaluronic acid research experience.

Name

Jinwoo Bio

Legal name

Jinwoo Bio Co., Ltd.

Website

https://jinwoobio.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Jinwoo Bio is a South Korean biotech company founded in 2013 that commercializes the world's first Solid Hyaluronic Acid Technology Platform (SHTP), selling the JiNu Patch medical wound dressing and Hi-Aqua cosmetic products to hospitals, dermatology clinics, and the cosmetics industry.

Ownership category

akta.pro rank

Product category

Medical Devices (Wound Care)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Hyaluronic acid medical devices
• Solid HA technology
• Wound dressing products
• Cosmetic ingredients
• Biotech manufacturing

Headquarters

HQ city

Yongin

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sales of SHTP-based medical devices including JiNu Patch (wound dressing), HA Thread (filler), and planned products like HA Wool and HA Fabric Sheet for wound care and plastic surgery applications
2. Cosmetic Products: Hi-Aqua brand platform sells cosmetic ingredients and products based on SHTP technology, targeting beauty and anti-aging market
3. Future Mucosal DDS Products: Development target for mucosal drug delivery system that can replace conventional injectable drugs, aimed at completing commercialization as a biopharmaceutical finished product

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Jinwoo Bio develops and manufactures medical devices and cosmetic products based on its proprietary Solid Hyaluronic Acid Technology Platform (SHTP), which solidifies hyaluronic acid into fiber, film, wool, and fabric-sheet forms. Its currently commercialized product is JiNu Patch, a Class II hyaluronic acid transparent wound dressing, sold to hospitals, dermatology clinics, and plastic surgery centers in Korea, with a pipeline of HA Thread, HA Wool, HA Fabric Sheet, and a mucosal drug delivery system, plus the Hi-Aqua cosmetic ingredient and product brand.

Product overview

Jinwoo Bio is a biotech company specializing in the Solid Hyaluronic Acid Technology Platform (SHTP), which enables the production of hyaluronic acid in solid forms (fiber, film, sheet) with high mechanical properties. The company offers a portfolio consisting of the released JiNu Patch product for wound care, along with planned products including HA Thread (facial implant filler), HA Wool (wound dressing material), and HA Fabric Sheet (multi-purpose wound care and drug delivery). The Hi-Aqua® brand platform extends from raw ingredients to finished cosmetic products, creating a unified product ecosystem based on SHTP technology.

Differentiator

Problem solved

Functional benefit

Brands

• Hi-Aqua®: Brand platform for hyaluronic acid-based products ranging from ingredients to cosmetics. URL: http://hi-aqua.co.kr/ko/
• JiNu Patch

Products and services

• JiNu Patch (진우패치) A hyaluronic acid transparent wound dressing patch that protects damaged skin; classified as a Class II medical device (adhesive transparent wound dressing). Sold to hospitals, dermatology clinics, and plastic surgery centers.
• Hi-Aqua® Brand Platform A brand platform spanning from raw HA-based ingredients to finished cosmetic products, including sheet masks, covering the entire hyaluronic acid product value chain using SHTP technology. Targets cosmetics manufacturers and brand customers.

Quantifiable outcome

• Side effect risk reduction (skin necrosis)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Anika Therapeutics: US-based company developing hyaluronic acid-based therapeutic products for joint preservation, wound care, and ophthalmic uses. Comparable to Jinwoo Bio in advancing HA technology beyond injectables into solid/medical-device formats and in targeting wound-healing and orthopedic applications.
• Organogenesis: US-based regenerative medicine company focused on advanced wound care and skin/tissue regeneration products. Directly comparable to Jinwoo Bio's wound-healing and skin-regeneration device strategy via JiNu Patch and planned HA Wool/Fabric Sheet.
• Fidia Farmaceutici: Italian pharmaceutical company specializing in hyaluronic acid-based products across joint care, wound care, and aesthetics. Comparable to Jinwoo Bio as a vertically-integrated HA specialist with medical-device and pharmaceutical applications.
• Seikagaku Corporation: Japanese specialty biochemical company focused on hyaluronic acid-based pharmaceuticals and medical devices, including intra-articular injections and ophthalmic viscosurgical devices. Directly comparable to Jinwoo Bio as a hyaluronic-acid-specialist platform company developing HA derivatives for medical applications.

Broad incumbents

• LG Chem Life Sciences: Korean chemical/biotech conglomerate developing HA products, aesthetic fillers, and related biologics under one of Korea's largest industrial groups. Provides a comparable South Korean reference point combining HA manufacturing at scale with downstream medical-device commercialization, though at far greater breadth and capital base.
• Coloplast: Danish medical-device company with a wound and skin care business operating globally. Comparable on hospital-channel wound-care commercialization with broader product breadth than Jinwoo Bio's single launched wound dressing.
• Smith+Nephew: Global medical-device leader with a dedicated advanced wound management portfolio. Comparable to Jinwoo Bio's JiNu Patch and HA wound-care positioning through competing advanced wound dressings sold into hospitals.
• Amorepacific: Korean cosmetics conglomerate with extensive HA-ingredient R&D and skincare brands. Comparable on the Hi-Aqua cosmetics side of Jinwoo Bio's business, leveraging HA technology into anti-aging and skincare product portfolios at global scale.

Regional players

• Hugel: Korean aesthetics and biopharmaceutical company commercializing botulinum toxin, HA fillers, and cosmeceuticals. Comparable to Jinwoo Bio as a Korean-headquartered aesthetic/medical-device player pursuing HA-based filler products and global dermatology/plastic-surgery channels.
• Medytox: Korean biotech developing botulinum toxin and HA filler products for aesthetic and therapeutic indications. Comparable to Jinwoo Bio in targeting hospital/dermatology channels in Korea and globally with injectable/solid HA aesthetics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jinwoo Bio